Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

TG Therapeutics reports positive topline results from 2 Phase 3 MS trials

TG Therapeutics (NASDAQ:TGTX) reported positive topline data from its two Phase 3 trials evaluating ublituximab, an anti-CD20 monoclonal antibody, for the treatment of relapsing forms of multiple sclerosis (MS)...

December 10, 2020

Developments

Pluristem terminates Phase 3 critical limb ischemia trial

Pluristem Therapeutics (NASDAQ:PSTI) reported disappointing results from an interim analysis of its Phase 3 study evaluating PLX-PAD for the treatment of critical limb ischemia. Based on the interim analysis, the study...

December 9, 2020

Developments

Cytokinetics reports positive interim results from Phase 2 hypertrophic cardiomyopathy trial

Cytokinetics (NASDAQ:CYTK) reported positive interim results from the first cohort of its Phase 2 REDWOOD-HCM clinical trial evaluating CK-274 for the treatment of hypertrophic cardiomyopathy. In the first cohort, 21...

December 9, 2020

Executive Moves

PDS Biotechnology names Seth Van Voorhees as CFO

Seth Van Voorhees PDS Biotechnology (NASDAQ:PDSB) appointed Seth Van Voorhees, Ph.D., as its new CFO, effective Jan. 1, 2021. He replaces Michael King, who served as interim CFO. Dr. Van Voorhees most recently was CFO...

December 9, 2020

Markets

BTIG starts Aerpio Pharma at buy: PT $4

BTIG launched coverage of Aerpio Pharmaceuticals (NASDAQ:ARPO) with a “buy” rating and $4 price target. The stock closed at $2 on Dec. 8. “Aerpio is marching forward with several clinical programs of its first-in-class...

December 9, 2020

Markets

Stifel starts Venus Concepts at hold; PT $2.50

Stifel initiated coverage of Venus Concepts (NASDAQ:VERO) with a “hold” rating and price target of $2.50, citing “more work to be done in improving ARTAS,” the company’s robotic hair restoration system. The stock closed...

December 9, 2020

Markets

HCW ups Curis PT to $9 from $5

H.C. Wainwright raised its price target for Curis (NASDAQ:CRIS) to $9 from $5 after the company announced preliminary data from an ongoing Phase 1 study evaluating monotherapy, CA-4948, in relapsed or refractory acute...

December 8, 2020

Developments

BELLUS Health doses first patient in Phase 2b chronic cough trial

BELLUS Health (NASDAQ:BLU; TSX:BLU) dosed the first patient in its Phase 2b study evaluating BLU-5937 for the treatment of refractory chronic cough. The study, called SOOTHE, will evaluate three doses of BLU-5937 in...

December 8, 2020

Developments

electroCore reports positive topline results from migraine prevention study

electroCore (NASDAQ:ECOR) reported positive topline results from its PREMIUM II study evaluating gammaCore, a non-invasive vagus nerve stimulation (nVNS) device, for the prevention of migraines. The study was designed...

December 8, 2020

Markets

HCW starts Prothena at buy; PT $22

H.C. Wainwright launched coverage of Prothena (NASDAQ:PRTA) with a “buy” rating and price target of $22. The stock closed at $11.53 on Dec 4. Prothena is focused on protein-opathies affecting the central nervous system...

December 7, 2020

Markets

HCW starts BiomX at buy; PT $20

H.C. Wainwright initiated coverage of BiomX (NYSE American:PHGE) with a “buy” rating and $20 price target. The stock closed at $5.90 on Dec 4. “BiomX is one of the leaders in the development of bacteriophage (phage)...

December 7, 2020

Developments

Precision BioSciences reports positive interim data from Phase 1/2a lymphoma, leukemia study

Precision BioSciences (NASDAQ:DTIL) reported positive interim results from its Phase 1/2a study evaluating PBCAR0191, an allogeneic chimeric antigen receptor (CAR-T) cell therapy, for the treatment of...

December 4, 2020

Subscribe